Presbyopia

The PDUFA date for Brimochol PF is January 28, 2026.

While the study included a range of patients in a variety of stages of presbyopia, the change in crystalline lens and anterior segment geometry was most pronounced in emmetropic and myopic presbyopes.

Brimochol PF’s combination of brimonidine and carbachol produces a “pinhole effect,” which is intended to improve depth of focus and sharpen near and distant impact.

The lens has been introduced to select practices across the US, with broad commercial availability planned for in May.

The novel corrective eye drop can be prescribed through pharmacy partners BlinkRx or Medvantx.

The new lenses are designed for young presbyopes, ranging in age from their late 30s to mid-40s, who may be either existing spectacle wearers or non-wearers.

Understanding the precise formulation of pharmacologic agents for refractive correction for presbyopia.

Cecelia Koetting, OD, FAAO, DipABO, and Madeline Yung, MD, discussed emerging treatment and patient care options for those with presbyopia during CRU 2025.

The 6th World Congress of Optometry will be held during Saudi Society of Optometry’s 11th Optometry Conference and Exhibition.

Updates include enrollments for LYNX-2 pivotal Phase 3 and VEGA-3 pivotal Phase 3 trials, in addition to a US FDA Fast Track Designation granted for phentolamine 0.75% for the treatment of significant chronic night driving impairment in keratorefractive patients with reduced mesopic vision.

Attention to patients' near visual needs is warranted when choosing medications.

Two posters presented research conducted on the optical design used in MyDay Energys and Biofinity Energys.

The 3-arm, multicenter, randomized, double masked, safety and efficacy study successfully met pre-specified visual acuity primary endpoints with statistically significant near vision improvements recorded at all time points over 8 hours.

74% of participants dosed with LNZ100 achieved 3 or more lines of improvement 3 hours post-treatment.

The company previously released positive data results from the pivotal Phase 3 CLARITY study in April, with the NDA submitted in August of this year.

The TECNIS Odyssey IOL is a new full vision range IOL built on the TECNIS platform.

Published data from a pair of Phase 3 clinical trials demonstrated a reversal of pharmacologically-induced mydriasis with a favorable safety profile, according. to the company.

Top-line data from the trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia are expected in 2025.

LNZ100 is an aceclidine-based ophthalmic solution and demonstrated statistically significant results in the Phase 3 CLARITY study.

Key steps include getting a new refraction, nailing the add power, and managing patient expectations.

How to personalize multifocal contact lens recommendations for your patients.

Results from the THRIVE study found that when reading glasses were given to first-time wearers, monthly median incomes increased by 33%.

The company selected LNZ100, designed to treat presbyopia, as its lead candidate and expects to submit an NDA in mid-2024.

Hear how this daily disposable silicone hydrogel option fits patients' busy and active lifestyles.

Even if DLS is completely normal and expected, it can be mentally and emotionally difficult for patients.

Here’s why formulation matters.

Qlosi (Orasis Pharmaceuticals) approved to treat presbyopia.

CSF-1 (0.4% pilocarpine HCl), a presbyopia-correcting drop candidate from Orasis, demonstrated consistent pupil restriction, which also suggests neuroadaptation in patients with presbyopia to the drop over time.